Why the U.S. lags in approving a nasal Covid vaccine

from POLITICO's Pulse Check · host POLITICO

Foreign rivals are developing nasal vaccines that could stop Covid transmission and a U.S. company invented the nasal vaccine that an Indian drugmaker licensed. But in the United States, Congress can’t agree on how to pay for additional money to fund next-generation Covid vaccines. Carmen Paun about her reporting with Megan Messerly. Plus, Dr. David Curiel on developing the nasal Covid-19 vaccine that Indian drugmaker Bharat Biotech has licensed. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode metadata supplied by the publisher feed · Published Oct 11, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Why the U.S. lags in approving a nasal Covid vaccine

0:00 11:50

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of POLITICO's Pulse Check?

This episode is 11 minutes long.

When was this POLITICO's Pulse Check episode published?

This episode was published on October 11, 2022.

Can I download this POLITICO's Pulse Check episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!